Advertisement

Topics

Celltrion Company Profile

23:26 EDT 19th September 2018 | BioPortfolio

Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost structure and strategic location in the rapidly growing Asian pharmaceutical markets make us an ideal choice for clients seeking world-class contract manufacturing services.
Celltrion's 23-acre manufacturing operation is located at the center of the high-technology park in Songdo New City, a new high-technology complex in the Incheon Metropolitan City , South Korea. The Celltrion facility is in close proximity to both the Incheon International Airport and downtown Seoul. Construction of Celltrion's 50,0000-liter capacity biopharmaceutical manufacturing facility, which is expected to be ready for commercial operation by early 2006, is being designed to comply with the cGMP (current Good Manufacturing Practices) Standards of the U.S. Food and Drug Administration and EMEA. The capacity can be quickly expanded to 150,000 liters based on client demand.

Location

13-6 Songdo-Dong
Yeonsu-Gu
Icheon City
406-840
KR

Contact

Phone: 82 32-850-5000
Fax: 82 32-850-5040
Email: celltrion@celltrion.com


News Articles [93 Associated News Articles listed on BioPortfolio]

Federal judge: Celltrion's Inflectra does not infringe on Remicade patent

Celltrion won against Johnson & Johnson unit Janssen Biotech's patent-infringement lawsuit regarding Celltrion's biosimilar I -More- 

Rejection: FDA Issues CLRs for Two Celltrion and Teva Biosimilars

The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.

FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a proposed trastuzumab biosimilar, issuing Complete Response Le...

Celltrion Completes Resubmission to FDA for CT-P6, a Proposed Trastuzumab Biosimilar

INCHEON, South Korea–(BUSINESS WIRE)–Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed m...

US FDA rejects Teva biosimilars made at troubled Celltrion plant

The US FDA has issued complete response letters (CRL) for the Rituxan and Herceptin biosimilar candidates after Celltrionâs facility received a warning in Janaury.

Celltrion Completes Resubmission for Biosimilar Candidate CT-P10 to FDA for Review

INCHEON, South Korea–(BUSINESS WIRE)–Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P10 (rituximab),...

Celltrion hit with Form 483 over troublesome Incheon plant

Celltrion has told shareholders its manufacturing site received a Form 483 from the US FDA.

Celltrion’s drive remains relentless despite being joined on ‘lonely path’ by host of biosimilar manufacturers

It was no fluke when Celltrion Healthcare became the first drug developer to win approval for a biosimilar…

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis

A new subcutaneous infliximab formulation is being developed by Celltrion, Inc. as an alternative to the intravenous regimen where subcutaneous infliximab injection typically takes less th...

Companies [5 Associated Companies listed on BioPortfolio]

Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltr...

Celltrion, Inc.

Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mA...

Celltrion

Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost ...

Teva Pharmaceutical Industries Ltd. and Celltrion, Inc.

Celltrion Healthcare

Satellite symposium 3a: Remsima™, the 1st biosimilar monoclonal antibody, Friday 20 February 07:15-08:15

More Information about "Celltrion" on BioPortfolio

We have published hundreds of Celltrion news stories on BioPortfolio along with dozens of Celltrion Clinical Trials and PubMed Articles about Celltrion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celltrion Companies in our database. You can also find out about relevant Celltrion Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record